Working with the NHS


AstraZeneca’s relationship with the NHS is at the centre of our UK Marketing Company activities.

The NHS is the primary customer for AstraZeneca medicines in the UK and we engage with NHS staff on many levels on a daily basis.
 
We interact with healthcare professionals as part of our sales and marketing work, ensuring that clinicians have the best access to information about our medicines in order to make appropriate prescribing decisions.
 
At both national and local level, we work closely with NHS staff to help facilitate decision-making and budgetary planning. We’re committed to ensuring that AstraZeneca’s business is aligned with NHS priorities and supports delivery of excellent patient care.
 
Our UK Marketing Company takes a wholly customer- centric approach to our relationships with the NHS. This enables us to work more collaboratively through a better understanding of the needs of the healthcare professionals, commissioners and patients who use our medicines

Joint Working with the NHS

Joint Working provides the formal foundation for creating, developing and implementing innovative healthcare solutions, which deliver better health outcomes for patients and the NHS.  The Department of Health defines Joint Working as “sSituations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery”.

The Department of Health and the Association of the British Pharmaceutical Industry (ABPI), of which AstraZeneca is a member, have worked together to produce valuable guidance to ensure that these partnerships are approached in the right way.

AstraZeneca has undertaken over 30 joint working projects since 2009.  Through these partnerships, we were able to work with the NHS to pool skills, experience and resources to benefit patients. 

By applying combining our resources and expertise to improve patients’ lives, successful projects we can improve the lives of patients in line with best practice NICE and NHS guidelines, as well ensuring that more people can access the innovative medicines they need, build trust with our NHS stakeholders and help the NHS achieve its targetsits objectives, as well ensuring that more people can access the innovative medicines they need, and can also provide a commercial return to AstraZeneca.when they need them.

The Department of Health and the Association of the British Pharmaceutical Industry (ABPI), of which AstraZeneca is a member, have worked together to produce valuable guidance to ensure that these partnerships are approached in the right way. AstraZeneca has a commitment to openness and transparency with regard to any donations, sponsorship or partnership funding it provides and, in line with the ABPI Code of Practice, will document and publicly disclose transfers of value made directly or indirectly to health professional and healthcare organisation.

This may need to be checked by compliance as they may have specific wording for this…it also might be useful to include a link to where we post our transfers of value.

Grants Provided to Institutions in 2014

As well as joint working with the NHS, AstraZeneca also provides occasional grants to the NHS, affiliated research institutions and other Healthcare Organisations (HCOs). Such grants are made according to AstraZeneca policy and procedure for projects benefitting patient care and / or medical research. It is a requirement of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice requirement to disclose such grants. Payments to individual Healthcare Organisations to sponsor and support educational meetings are currently not required to be disclosed under the current ABPI Code of Practice. AstraZeneca is fully committed to transparency and will be disclosing sponsorship payments and also fees for services made to individual HCOs from 2015 onwards in line with the requirements of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code and ABPI Code of Practice.


Grants Provided to Institutions in 2014

Institution
Nature of Support
Funding Amount
University of Bristol
 
Research Grant for an infectious disease study
£32,377
Ovarian Cancer Action
 
Grant to support a disease awareness campaign directed to general practitioners
 
£19,000
National Heart and Lung Institute, Imperial College London
 
Contribution towards the cost of the development of a mobile app incorporating the national treatment guidelines
£18,480
UK Lung Cancer Coalition
 
Corporate membership fee that is used to support the activities of this organisation
 
£5,000
Primary Care Respiratory Society UK
 
Corporate membership fee that is used to support the activities of this organisation
£27,000
Association of Respiratory Nurse Specialists
 
Corporate membership fee that is used to support the activities of this organisation
£12,000
St. Georges University London
 
Grant to support a national screening programme for a specific patient group at increased risk of cardiovascular events
£12,500
British Thoracic Society
Part funding of a study to identify and evaluate the impact of a nurse specialist intervention on patient health outcomes. 
 
£10,000
UK Oncology Nursing Society
 
Corporate membership fee that is used to support the activities of this organisation
£8,000
Paula Carr Trust
Grant to support a healthcare professional training program and implementation of an integrated care pathway project involving a number of CCGs in East Kent
 
£20,000
Paula Carr Trust
Grant to support a healthcare professional training program in West Kent CCG and Maidstone and Tunbridge Wells NHS Trust
 
£4,300
NHS Greater Glasgow & Clyde
Grant to support participation in an education for health diploma level asthma module for prescribing support pharmacists
 
£1,272
Wessex Academic Health Science Network
Grant to support the implementation of the second phase of a community pharmacy respiratory disease screening programme
£10,000
 
Grants made by Global Functions within AstraZeneca in 2014
 
Institution
Nature of Support
Funding Amount
British Association for Cancer Research (BACR)
Support for BACR Young Scientist Award and support for a keynote lecture at the National Cancer Research Institute Conference
£5,000

All sums above are inclusive of VAT where applicable


Joint Working can include:

  • AstraZeneca employee time
  • Nursing support
  • Commissioning advice
  • Help developing patient pathways
  • Screening services
  • Data analysis